Vialogy Share Discussion Threads

[michaelx105] 30/6/2014 12:26

Tipped. 50% gain within a month predicted.

[the prophet] 30/6/2014 12:01

just a reminder


The Prophet
29 Jun'14 - 11:27 - 11187 of 11191 0 0 edit

have started a new thread for Premaitha Health here



slightly previous, as Premaitha starts to trade as from this coming Friday, post the GM on thursday.

Please feel free to use this thread or the new one up to Friday, but thought I would kick off a new one as I'm not sure if I will be about on Friday.

[michaelx105] 30/6/2014 11:55

Lovely bounce today.

[gekko68] 29/6/2014 11:47

Premaitha Health's executive management team is led by Dr Stephen Little, a successful serial biotechnology entrepreneur who has a proven diagnostic and commercial track record. He has assembled similarly talented and experienced team of individuals with the skills, knowledge and background needed to bring a prenatal screening product to market.

Commenting on today's news, Dr Stephen Little CEO at Premaitha Health said:
"Our approach is to take early stage discoveries and translate them into clinically useful diagnostic products that can be widely used to benefit human health. As we build and commercialise the IONA® test, we are not only building a valuable in vitro diagnostic product in its own right but also establishing a template for creating valuable diagnostic content on third parties' next generation sequencing systems." Dr Little added: "The global market for prenatal testing is estimated at $4.2 billion and this is an exciting phase in our development of the business roll-out so we are looking forward to working with the new team and delivering on our plans for the IONA® test."

The technology used in the IONA® test will be new to many potential customers. Premaitha is in the process of establishing a demonstration laboratory at its Manchester headquarters. This laboratory will reproduce the complete IONA® Test workflow so that customers can test their own samples and be trained in the process.

The highly qualified team of scientists and technicians at Premaitha are also currently undergoing IONA® Test development and design verification processes; target completion for this stage is by 30 September 2014. The clinical performance and commercialisation testing is then anticipated to be substantially complete by 31 December 2014 with expected commercial launch of the IONA® test to commence January 2015.

The targeted customers for the IONA® test are the estimated 600 laboratories offering prenatal screening within the EMEA region as well as similar labs throughout the rest of the world. Premaitha's primary channel to market will be through its own direct sales force targeting laboratory directors supported by activities to target and gain support of key opinion leaders. Following the initial launch in Europe, it is the intention to extend sales and marketing activities in to Asia.
ENDS

Media Enquiries:
Fiona Tooley, TooleyStreet Communications
[e-mail] or M: 07785 703 523

For further information: read about us at www.premaitha.com or call [phone] or email us on [e-mail]: :Visit our stand at the 13th World Congress in Fetal Medicine 29 June to 3 July 2014 Nice, France hxxp://fetalmedicine.org/fmf-world-congress-1
Premaitha to join AIM and launch exciting NIPT to improve prenatal screening globally
UK: Friday 13 June 2014: Molecular Diagnostics Company, Premaitha Health , based in Manchester's

[gekko68] 29/6/2014 11:41

Premaitha Health's executive management team is led by Dr Stephen Little, a successful serial biotechnology entrepreneur who has a proven diagnostic and commercial track record. He has assembled similarly talented and experienced team of individuals with the skills, knowledge and background needed to bring a prenatal screening product to market.

Commenting on today's news, Dr Stephen Little CEO at Premaitha Health said:
"Our approach is to take early stage discoveries and translate them into clinically useful diagnostic products that can be widely used to benefit human health. As we build and commercialise the IONA® test, we are not only building a valuable in vitro diagnostic product in its own right but also establishing a template for creating valuable diagnostic content on third parties' next generation sequencing systems." Dr Little added: "The global market for prenatal testing is estimated at $4.2 billion and this is an exciting phase in our development of the business roll-out so we are looking forward to working with the new team and delivering on our plans for the IONA® test."

The technology used in the IONA® test will be new to many potential customers. Premaitha is in the process of establishing a demonstration laboratory at its Manchester headquarters. This laboratory will reproduce the complete IONA® Test workflow so that customers can test their own samples and be trained in the process.

The highly qualified team of scientists and technicians at Premaitha are also currently undergoing IONA® Test development and design verification processes; target completion for this stage is by 30 September 2014. The clinical performance and commercialisation testing is then anticipated to be substantially complete by 31 December 2014 with expected commercial launch of the IONA® test to commence January 2015.

The targeted customers for the IONA® test are the estimated 600 laboratories offering prenatal screening within the EMEA region as well as similar labs throughout the rest of the world. Premaitha's primary channel to market will be through its own direct sales force targeting laboratory directors supported by activities to target and gain support of key opinion leaders. Following the initial launch in Europe, it is the intention to extend sales and marketing activities in to Asia.
ENDS

Media Enquiries:
Fiona Tooley, TooleyStreet Communications
[e-mail] or M: 07785 703 523

For further information: read about us at www.premaitha.com or call [phone] or email us on [e-mail]: :Visit our stand at the 13th World Congress in Fetal Medicine 29 June to 3 July 2014 Nice, France hxxp://fetalmedicine.org/fmf-world-congress-1
Premaitha to join AIM and launch exciting NIPT to improve prenatal screening globally
UK: Friday 13 June 2014: Molecular Diagnostics Company, Premaitha Health , based in Manchester's

[gekko68] 29/6/2014 11:36

Looks less of a gamble does it not? There is allot of interest in this new product.


Are pleased to announced 597 labs have signed up to use iona test from Jan 1. Contract details to follow shortly.
That would be nice on company change day :-)

[the prophet] 29/6/2014 11:27

have started a new thread for Premaitha Health here



slightly previous, as Premaitha starts to trade as from this coming Friday, post the GM on thursday.

Please feel free to use this thread or the new one up to Friday, but thought I would kick off a new one as I'm not sure if I will be about on Friday.

[ewads] 29/6/2014 11:18

'I only buy shares that go up,that's how you make money'

Sounds good to me , i'll give it a try.

[gekko68] 29/6/2014 09:26

Azuli - I have done well with my investments,all investments are a gamble. You should set yourself a stop-loss in all your investments. You cant be right with all of them,if you make a mistake then admit it & move on. I have found allot of people who lose money blame others for making bad decisions,when they are to blame. I do not buy into companies based on anything that is said on these boards,i do research & looks at charts.
One problem with these boards is they often get clogged up with disgruntles investors who don't really have anything to add,they do no research.
These shares are going up & people are buying,so long as this is happening anyone invested will make money. I only buy shares that go up,that's how you make money.
Anyone wishing to make a comment,do some research first. I admit this was a garbage company,run by a director who was a complete clown who was only interested in lining his own pockets. But we now have a director who has a proven track record of turning companies around. There product wont come to the market until January. So the way i look at it is,anyone investing will have a free ride due to the demand in shares,they where over subscribed by %400. You could sell before there product comes to the market or take a gamble that they actually make meaningful sales.

[spec7] 29/6/2014 06:45

Azuli
The AIM has been set up to strip punters of their money, the CEO's MD's FD's brokers, market makers,fund managers tipsters and banks all want a cut of your "investment" The sad fact is that 78% of AIM investors lose their money. Its fuelled by greed and most would be guaranteed to do better on the premium bonds but like the lottery the AIM lures people with talk of big prizes, 10 baggers, no brainers and dead certs. These boards play a huge part, without them i doubt the AIM would even exist !! but still people pile money into investments they really know nothing about in companies that never give you the full picture promoted by faceless pseudonym names in a free chat room.
Put your investments in blue chip, fund managed bonds with a return and use the AIM to gamble pocket money but never never put anything in the AIM you cant afford to lose and expect too lose.

[gekko68] 28/6/2014 23:08

Would agree with you about this company a decade ago or even a few months ago. They now have a new director & the cancer that was eating away at the company is gone. You never heard of a turnaround? I buy into turnaround companies & have done quite well by it. Why not do more research before making comments. Had one guy who was invested in a bus company that was going nowhere come on. If he made better investment decision he could actually buy are car instead of getting a bus. All that matters is a share price goes up. This company did a reverse takeover of another company. The new shares where %400 over prescribed.

[gekko68] 28/6/2014 21:31

Premaitha Health's executive management team is led by Dr Stephen Little, a successful serial biotechnology entrepreneur who has a proven diagnostic and commercial track record. He has assembled similarly talented and experienced team of individuals with the skills, knowledge and background needed to bring a prenatal screening product to market.

Commenting on today's news, Dr Stephen Little CEO at Premaitha Health said:
"Our approach is to take early stage discoveries and translate them into clinically useful diagnostic products that can be widely used to benefit human health. As we build and commercialise the IONA® test, we are not only building a valuable in vitro diagnostic product in its own right but also establishing a template for creating valuable diagnostic content on third parties' next generation sequencing systems." Dr Little added: "The global market for prenatal testing is estimated at $4.2 billion and this is an exciting phase in our development of the business roll-out so we are looking forward to working with the new team and delivering on our plans for the IONA® test."

The technology used in the IONA® test will be new to many potential customers. Premaitha is in the process of establishing a demonstration laboratory at its Manchester headquarters. This laboratory will reproduce the complete IONA® Test workflow so that customers can test their own samples and be trained in the process.

The highly qualified team of scientists and technicians at Premaitha are also currently undergoing IONA® Test development and design verification processes; target completion for this stage is by 30 September 2014. The clinical performance and commercialisation testing is then anticipated to be substantially complete by 31 December 2014 with expected commercial launch of the IONA® test to commence January 2015.

The targeted customers for the IONA® test are the estimated 600 laboratories offering prenatal screening within the EMEA region as well as similar labs throughout the rest of the world. Premaitha's primary channel to market will be through its own direct sales force targeting laboratory directors supported by activities to target and gain support of key opinion leaders. Following the initial launch in Europe, it is the intention to extend sales and marketing activities in to Asia.
ENDS

Media Enquiries:
Fiona Tooley, TooleyStreet Communications
[e-mail] or M: 07785 703 523

For further information: read about us at www.premaitha.com or call [phone] or email us on [e-mail]: :Visit our stand at the 13th World Congress in Fetal Medicine 29 June to 3 July 2014 Nice, France hxxp://fetalmedicine.org/fmf-world-congress-1
Premaitha to join AIM and launch exciting NIPT to improve prenatal screening globally
UK: Friday 13 June 2014: Molecular Diagnostics Company, Premaitha Health , based in Manchester's

[gekko68] 28/6/2014 21:30

Premaitha Health's executive management team is led by Dr Stephen Little, a successful serial biotechnology entrepreneur who has a proven diagnostic and commercial track record. He has assembled similarly talented and experienced team of individuals with the skills, knowledge and background needed to bring a prenatal screening product to market.

Commenting on today's news, Dr Stephen Little CEO at Premaitha Health said:
"Our approach is to take early stage discoveries and translate them into clinically useful diagnostic products that can be widely used to benefit human health. As we build and commercialise the IONA® test, we are not only building a valuable in vitro diagnostic product in its own right but also establishing a template for creating valuable diagnostic content on third parties' next generation sequencing systems." Dr Little added: "The global market for prenatal testing is estimated at $4.2 billion and this is an exciting phase in our development of the business roll-out so we are looking forward to working with the new team and delivering on our plans for the IONA® test."

The technology used in the IONA® test will be new to many potential customers. Premaitha is in the process of establishing a demonstration laboratory at its Manchester headquarters. This laboratory will reproduce the complete IONA® Test workflow so that customers can test their own samples and be trained in the process.

The highly qualified team of scientists and technicians at Premaitha are also currently undergoing IONA® Test development and design verification processes; target completion for this stage is by 30 September 2014. The clinical performance and commercialisation testing is then anticipated to be substantially complete by 31 December 2014 with expected commercial launch of the IONA® test to commence January 2015.

The targeted customers for the IONA® test are the estimated 600 laboratories offering prenatal screening within the EMEA region as well as similar labs throughout the rest of the world. Premaitha's primary channel to market will be through its own direct sales force targeting laboratory directors supported by activities to target and gain support of key opinion leaders. Following the initial launch in Europe, it is the intention to extend sales and marketing activities in to Asia.
ENDS

Media Enquiries:
Fiona Tooley, TooleyStreet Communications
[e-mail] or M: 07785 703 523

For further information: read about us at www.premaitha.com or call [phone] or email us on [e-mail]: :Visit our stand at the 13th World Congress in Fetal Medicine 29 June to 3 July 2014 Nice, France hxxp://fetalmedicine.org/fmf-world-congress-1
Premaitha to join AIM and launch exciting NIPT to improve prenatal screening globally
UK: Friday 13 June 2014: Molecular Diagnostics Company, Premaitha Health , based in Manchester's

[gekko68] 28/6/2014 21:29

Premaitha Health's executive management team is led by Dr Stephen Little, a successful serial biotechnology entrepreneur who has a proven diagnostic and commercial track record. He has assembled similarly talented and experienced team of individuals with the skills, knowledge and background needed to bring a prenatal screening product to market.

Commenting on today's news, Dr Stephen Little CEO at Premaitha Health said:
"Our approach is to take early stage discoveries and translate them into clinically useful diagnostic products that can be widely used to benefit human health. As we build and commercialise the IONA® test, we are not only building a valuable in vitro diagnostic product in its own right but also establishing a template for creating valuable diagnostic content on third parties' next generation sequencing systems." Dr Little added: "The global market for prenatal testing is estimated at $4.2 billion and this is an exciting phase in our development of the business roll-out so we are looking forward to working with the new team and delivering on our plans for the IONA® test."

The technology used in the IONA® test will be new to many potential customers. Premaitha is in the process of establishing a demonstration laboratory at its Manchester headquarters. This laboratory will reproduce the complete IONA® Test workflow so that customers can test their own samples and be trained in the process.

The highly qualified team of scientists and technicians at Premaitha are also currently undergoing IONA® Test development and design verification processes; target completion for this stage is by 30 September 2014. The clinical performance and commercialisation testing is then anticipated to be substantially complete by 31 December 2014 with expected commercial launch of the IONA® test to commence January 2015.

The targeted customers for the IONA® test are the estimated 600 laboratories offering prenatal screening within the EMEA region as well as similar labs throughout the rest of the world. Premaitha's primary channel to market will be through its own direct sales force targeting laboratory directors supported by activities to target and gain support of key opinion leaders. Following the initial launch in Europe, it is the intention to extend sales and marketing activities in to Asia.
ENDS

Media Enquiries:
Fiona Tooley, TooleyStreet Communications
[e-mail] or M: 07785 703 523

For further information: read about us at www.premaitha.com or call [phone] or email us on [e-mail]: :Visit our stand at the 13th World Congress in Fetal Medicine 29 June to 3 July 2014 Nice, France hxxp://fetalmedicine.org/fmf-world-congress-1
Premaitha to join AIM and launch exciting NIPT to improve prenatal screening globally
UK: Friday 13 June 2014: Molecular Diagnostics Company, Premaitha Health , based in Manchester's

[gekko68] 28/6/2014 20:24

JSBach123 _ Your logic if a company is of any use it would be snapped up is complete nonsense. Surprised no one is snapping up optare with there share price being at a all time low. Ask your yourself why this company was over subscribed by over %400 & the share price is going up.

[gekko68] 28/6/2014 20:17

For someone who is not invested in optare,you sure spend allot of time on that board. Good luck.

[jsbach123] 28/6/2014 15:39

You make a presumption Gekko that is incorrect: I have not been invested in buses for four years or so.

I am quite content with the gains made on my portfolio over the last five years; one always has some duds but my gains have outweighed my losses comfortably. I post only on companies that intrigue me and 'are at the edge' or in which I continue to have an (academic) interest; so for example I don't post on M&S, Barclays, Elementis etc etc but have posted on OPE, VIY, TRP, AEX. Biotech companies are very high risk. Biotech companies that are subject to reverse takeovers from digital tech companies are..well...intriguing.

Good luck with your investments, all IMHO and no advice intended.

[jsbach123] 28/6/2014 15:32

I claim no superior knowledge though it is clear to me from your posting that you have not followed VIY for long. To answer your question Gekko I lost a few hundred pounds on the buses more than four years ago and have not held since but have continued to follow the company having done the research as to why I believed the spin and I comment upon it to correct the blatant ramping and misinformation that sometimes is posted.

However concerning VIY soon to be reincarnated going from a digital tech snake oil product to a medical diagnostic product still remains very high risk IMHO and if diagnostics was proven would IMHO have been snapped up. Medical/research communities are small and knowledge is shared widely and quickly among their members.

[jimb2] 28/6/2014 12:28

Thanks TP,

I'm looking forward to next weeks events, I wonder what the share price will be come Thursday/Friday?

GL

[gekko68] 28/6/2014 09:27

JSbach123 - There is a element of risk in all investments. However the risk is reduced when you have a competent director which we do. Higher the risk,higher the reward. How well are you doing with your investment in the bus company,lost much?
No offence your judgement when it comes to investments & risk does not look good.
You are invested in a bus company which is losing money & has increasing debt levels.

[the prophet] 28/6/2014 08:59

jimb2

good bit of research and very interesting, thanks.

[gekko68] 27/6/2014 22:58

JSBach123 - How much have you lost with your bus investment? Why not sell up & join us? Or just watch as our shares go up & yours go down.